Elisabeth B.
- Country
- The Netherlands
- Department
- Rheumatology and Clinical Immunology
Research Overview
- Efficacy of Rituximab in Reducing Glucocorticoid Exposure in Patients with Relapsing Polymyalgia Rheumatica: A Randomized Controlled Trial
- Evaluation of [18F]Fluoro-PEG-Folate PET/CT Imaging in Active Giant Cell Arteritis Patients Pre- and Post-Standard Treatment
- A Multicenter Randomized Placebo-Controlled Study of Leflunomide for Relapse Prevention in Polymyalgia Rheumatica During Corticosteroid Tapering
Data & Insights
Has run more than one trial at 2 of 12 partner sites.
Specializations
Rheumatological Imaging
Specializes in advanced imaging techniques using positron emission tomography (PET) for rheumatological conditions, with particular focus on macrophage targeting in pre-clinical arthritis detection.
- Innovative PET imaging for arthritis prediction
- Macrophage-targeted molecular imaging
- Early detection of rheumatoid conditions
Conducts research in whole-body imaging techniques for early disease identification and monitoring.
Inflammatory Vascular Conditions
Investigates giant cell arteritis (GCA) through specialized arterial imaging techniques, focusing on disease activity assessment and treatment monitoring.
- Vascular inflammation imaging
- Treatment response evaluation
- Large vessel assessment
Utilizes advanced PET/CT imaging protocols for vascular inflammation visualization.
Polymyalgia Rheumatica Research
Leads investigations in polymyalgia rheumatica (PMR) treatment approaches, focusing on novel therapeutic interventions and long-term disease management.
- Biological therapy assessment
- Long-term treatment outcomes
- Glucocorticoid-sparing strategies
Explores innovative treatments including rituximab and secukinumab for PMR management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.